Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.13)
# 2,966
Out of 5,090 analysts
37
Total ratings
48.48%
Success rate
-5.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Outperform | $40 | $21.90 | +82.65% | 1 | Dec 1, 2025 | |
| FBRX Forte Biosciences | Initiates: Outperform | $65 | $19.93 | +226.14% | 1 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $775 → $910 | $901.17 | +0.98% | 5 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $20 → $14 | $1.71 | +718.71% | 4 | Sep 22, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $207 → $222 | $226.08 | -1.80% | 5 | Sep 22, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $77 → $89 | $68.48 | +29.96% | 3 | Aug 8, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $2.09 | +139.23% | 1 | Apr 29, 2025 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $12.35 | +86.23% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $2.55 | +135.29% | 2 | Dec 20, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $22.26 | +663.70% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $4.36 | +358.72% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $201 → $206 | $234.13 | -12.01% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $2.92 | +653.42% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.67 | +274.53% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $89.47 | -32.94% | 1 | Oct 5, 2022 |
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $21.90
Upside: +82.65%
Forte Biosciences
Nov 25, 2025
Initiates: Outperform
Price Target: $65
Current: $19.93
Upside: +226.14%
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $775 → $910
Current: $901.17
Upside: +0.98%
Jasper Therapeutics
Sep 22, 2025
Maintains: Outperform
Price Target: $20 → $14
Current: $1.71
Upside: +718.71%
AbbVie
Sep 22, 2025
Maintains: Outperform
Price Target: $207 → $222
Current: $226.08
Upside: -1.80%
Mirum Pharmaceuticals
Aug 8, 2025
Maintains: Outperform
Price Target: $77 → $89
Current: $68.48
Upside: +29.96%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $2.09
Upside: +139.23%
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $12.35
Upside: +86.23%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.55
Upside: +135.29%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $22.26
Upside: +663.70%
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $4.36
Upside: +358.72%
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $234.13
Upside: -12.01%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $2.92
Upside: +653.42%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.67
Upside: +274.53%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $89.47
Upside: -32.94%